schizophrenia

October 1, 2018

Cytokine-cognition connection

Targeting the immune system may provide a new avenue for therapeutic intervention in psychiatric diseases characterized by motivational and cognitive deficits.

By Laura Daniel
June 14, 2018

Shared genetics may shape treatment options for certain brain disorders

Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University and Virginia Commonwealth University is reporting.

By Bill Snyder
March 9, 2018

Brain connections in schizophrenia

Brain imaging studies have implicated the connection between two brain regions in the pathophysiology of schizophrenia.

By Leigh MacMillan
Istock image of neurons in the brain
January 8, 2018

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

By Bill Snyder
elderly Asian mother and adult daughter
August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

By Bill Snyder
December 27, 2016

Investigational new drug for Alzheimer’s scheduled for first study in humans

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer’s disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

By Craig Boerner
September 15, 2016

Researchers eye potential schizophrenia ‘switch’

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
By Bill Snyder
August 15, 2016

Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.
By Bill Snyder
March 21, 2016

Putting schizophrenia to bed

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.
By VUMC News and Communications
August 21, 2015

Brain circuitry in psychosis

Functional magnetic resonance imaging has revealed faulty circuits between the thalamus – a central hub of brain activity – and other brain regions.
By Leigh MacMillan
July 9, 2015

Signals of schizophrenia

Vanderbilt researchers have discovered a possible molecular mechanism of schizophrenia that could lead to new treatments for the disorder.
By VUMC News and Communications
June 16, 2015

A view of brain function in disease

Vanderbilt investigators report the first use of a specialized type of MRI to study the hippocampus in patients with schizophrenia.
By Leigh MacMillan
May 7, 2015

Findings reveal new target in quest to ease schizophrenia

Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
By Bill Snyder
1 2 3 4